Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer ...

The latest trading session saw Johnson & Johnson (JNJ ... world's biggest maker of health care products had lost 6.9% over the past month. This has lagged the Medical sector's loss of 3.8% ...

Johnson & Johnson (JNJ ... world's biggest maker of health care products have depreciated by 7.4% over the course of the past month, underperforming the Medical sector's loss of 7.03% and the ...

The changes include the renaming of Janssen, the company’s pharmaceutical segment, as Johnson & Johnson Innovative Medicine, while the brand will continue to incorporate the medical technology ...